Regeneron Stock Falls on Eylea Sales Decline, FDA Delays

Key Highlights of Regeneron's Q1 Report

Regeneron Pharmaceuticals (NASDAQ:REGN) experienced a significant stock decline of 5.24%, closing at $693.43, following the release of its first-quarter financial results. The drop was primarily driven by a 10% decrease in sales for its flagship eye-disease drug, Eylea.

Situational Overview

The company reported that Eylea sales fell to $941 million in the first quarter. This decline was partly attributed to lower wholesaler inventory levels affecting its higher-dose version, Eylea HD. Despite the sales miss, Regeneron posted adjusted earnings of $9.47 per share, outperforming the analyst consensus estimate of $8.94.

Market Impact and Analyst Outlook

According to RBC Capital Markets, the stock's negative performance was a reaction to several factors. Beyond the weaker-than-expected Eylea HD sales, investors were concerned about regulatory complications. The U.S. Food and Drug Administration (FDA) did not meet its target date for a decision on a second contract manufacturer for the pre-filled syringe version of Eylea HD. Adding to the pressure, Regeneron announced that an experimental drug combination for lung cancer would not proceed to late-stage trials.

Summary

While Regeneron's earnings beat provided a positive note, the market focused on the revenue miss from its key product, Eylea, and a series of regulatory and clinical trial disappointments. Investors will closely monitor future sales figures for Eylea HD and any updates from the FDA regarding manufacturing approvals.

FAQ

Q: Why did Regeneron's stock price drop?
A: The stock fell mainly due to a 10% decline in Q1 sales of its eye drug Eylea, delays in FDA approval for a pre-filled syringe version, and the discontinuation of a lung cancer drug trial.

Q: Did Regeneron meet its earnings expectations for the first quarter?
A: Yes, Regeneron reported adjusted earnings of $9.47 per share, exceeding analysts' estimates of $8.94 per share.

Source: Investing.com